Arrowhead Pharmaceuticals Q3 2020 Earnings Report
Key Takeaways
Arrowhead Pharmaceuticals reported revenue of $27.38 million and a net loss of $13.61 million for the third quarter of fiscal year 2020.
Earned a $20 million milestone payment from Amgen following the administration of the first dose of AMG 890 in a Phase 2 clinical study.
Hosted a key opinion leader webinar on ARO-ENaC, the company’s investigational RNAi therapeutic being developed as a treatment for patients with cystic fibrosis.
Completed dosing in healthy volunteer cohorts in AROHSD1001, a Phase 1/2 clinical study of ARO-HSD, being developed as a treatment for patients with alcohol related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis
Completed planned enrollment and dosing of 93 subjects in AROANG1001, a Phase 1/2 clinical study of ARO-ANG3, being developed for the treatment of mixed dyslipidemia